Oncolytics Biotech® Inc. (NASDAQ:ONCY) has announced positive data from the investigator-sponsored, ReoGlio phase 1b study. The company is evaluating pelareorep combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) versus standard of care chemoradiotherapy and adjuvant temozolomide in treating glioblastoma mutiforme.
Pelareorep combination with GM-CSF showed a favorable safety profile
The results were featured in a podium presentation at this year’s Annual Society of Neuro-Oncology Meeting. They demonstrated a clear efficacy signal and tolerability and safety of pelareorep-based combination therapy in GBM patients. Oncolytics Head of Clinical Development and operations, Thomas Heineman said that the ReoGlio study results show a robust set of clinical data supporting pelareorep’s safety and tolerability in several indications. Thomas said that the average progression-free survival or around eight months is encouraging for this challenging indication, especially considering the enhanced PFS correlated with administered pelareorep dose. He added that the results would drive momentum to develop pelareorep across a range of cancer indications.
Clinical Oncology and Neuro-Oncology Professor at University of Leed, Susan Short, gave the podium presentation. It was titled, “Pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) with standard chemoradiotherapy/adjuvant temozolomide for glioblastoma multiforme (GBM) patients: ReoGlio phase I trial result.” The estimated average PFS of all evaluable patients irrespective of pelareorep doses level was 7.8 months.
University of Leeds And Cancer Research UK co-sponsored the ReoGlio study
Oncloytics is still focused on the clinical advancement of pelareorep and will continue exploring new commercial openings for pelareorep. The company will also continue prioritizing its ongoing programs to achieve expected milestones for patie4nts with gastrointestinal, breast, and hematological malignancies. Oncolytics is grateful for the support from Cancer Research UK, The Brain Tumor Charity, and the University of Leeds to manage, design, and fund the ReoGlio study.
The investigator-sponsored Phase 1b, open-label ReoGlio study evaluated pelareorep and GM-CSF combination alongside standard chemoradiotherapy and temozolomide adjuvant in newly diagnosed GBM treatment. The study objective was determining maximum tolerable pelareorep and GM-CSF dose with standard chemoradiotherapy. The secondary objective was to gain a preliminary assessment of pelareorep-GM-CSF combination’s activity and treatment compliance.
